MedImmune Message Board - Msg: 20967367

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: steve kammerer who wrote (355)	1/20/2005 1:40:49 PM
From: sjemmeri	of 416

13:19 ET MedImmune files INDA for nasally delivered RSV/PIV-3 vaccine (MEDI) 24.68 +0.13: Co announces that is has filed an investigational new drug application to begin clinical studies of its respiratory syncytial virus (R.S.V.) and parainfluenza virus type-3 (PIV-3) candidate vaccine. Data from preclinical studies indicate that the combination vaccine elicited protective immune responses to R.S.V. and PIV-3, two leading causes of pediatric respiratory disease. Upon the FDA's review and approval of the INDA, MedImmune plans to initiate a Phase 1 clinical study for the RSV/PIV-3 candidate vaccine.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next